Conventional Medical Management of Inflammatory Bowel Disease
Section snippets
Approach to Care
The choice of treatment depends on disease activity and extent, as well as patient acceptability and mode of drug delivery. Disease activity is best confirmed (and infection excluded) before therapy is initiated or when response to therapy is slow. To optimize conventional therapy, it is important to carefully time the steps of treatment and explain the strategy to the patient.
Inducing Remission in Patients With UC
5-Aminosalicylates are the most common treatment for patients with mild (≤4 bloody stools/d) or moderately active disease (>4 bloody stools/d without systemic toxicity).6 Absorption must be prevented to achieve colonic delivery, either by administration of a prodrug (balsalazide, olsalazine, or sulfasalazine), a drug with a gastroresistant, pH-dependent coating (eg, Asacol, Salofalk), or a drug with a slow-release mechanism (eg, Pentasa).7 Nevertheless, the asymmetrical, right-to-left gradient
Inducing Remission of Patients With CD
The therapeutic strategies are broadly similar in CD and UC, although significant differences exist, including a limited or lack of response to mesalamine or cyclosporin, response to nutritional therapy, and greater need for surgery in CD.4, 5 Enthusiasm for biological therapy needs to be tempered with recognition that half will have a benign course; in a Norwegian, 10-year, population-based study, just 53% developed stricturing or penetrating disease.34 At diagnosis, it is possible to identify
Maintaining Remission of Patients With UC
In a population-based study of 1575 patients with UC, 13% had no relapse, 74% had ≥2 relapses, and 13% had active disease every year for 5 years after diagnosis.48 Oral mesalamine is the first-line maintenance therapy reducing the risk of relapse by 50% (odds ratio = 0.47 for failure to maintain clinical or endoscopic remission vs placebo).49 Clinical remission with complete discontinuation of corticosteroid use should be the goal of therapy for UC, but the definition of remission varies,
Maintaining Remission in Patients With CD
Cigarette smoking should be discouraged in patients with CD because it increases the need for steroid therapy and surgery.63 Mesalamine cannot be recommended for patients with CD, as results from meta-analyses are inconsistent. A Cochrane review found no benefit of mesalamine (odds ratio = 1.00 for maintaining medically induced remission over 12 months), but there may be differences among delivery systems.64, 65 Steroids should not be used to maintain remission either. Budesonide (6 mg) daily
Perianal CD
Antibiotics reduce fistula drainage, but in a randomized comparison, only 4 of 10 patients responded to ciprofloxacin, compared to 1 of 8 on metronidazole and 1 of 7 on placebo.77 The study was too small to show significant differences, but 5 of 8 could not tolerate metronidazole for 10 weeks. Azathioprine has only been assessed in retrospective studies; fistulae healed in approximately 33% of patients. Complex fistulizing CD warrants early introduction of anti-TNF agents, combined with
Conclusions
Common mistakes in conventional therapy include overprescription of mesalamine for CD, inappropriate use of steroids (for perianal CD in patients with sepsis or for maintenance), delayed introduction or underdosing with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate), and failure to consider timely surgery. The paradox of anti-TNF therapy is that although it is used inappropriately (when there is sepsis or a fibrostenotic stricture) or overused (for disease that would respond
Acknowledgments
We are grateful to Tim Orchard and Ailsa Hart for their views on the algorithms.
References (50)
- et al.
European evidence-based consensus on the management of ulcerative colitis: current management
J Crohns Colitis
(2008) - et al.
The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management
J Crohns Colitis
(2010) - et al.
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study
Gastroenterology
(2001) - et al.
The role of CMV in steroid-resistant ulcerative colitis: a systematic review
J Crohns Colitis
(2009) - et al.
Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression
Clin Gastroenterol Hepatol
(2007) - et al.
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study
Gastroenterology
(2005) - et al.
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
Gastroenterology
(2003) - et al.
Is keeping the colon the ultimate marker of success in ulcerative colitis?
Gastroenterology
(2009) - et al.
Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study
Clin Gastroenterol Hepatol
(2007) - et al.
Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials
Clin Gastroenterol Hepatol
(2004)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials
Clin Gastroenterol Hepatol
Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee
Am J Gastroenterol
The Asia-Pacific consensus on ulcerative colitis
J Gastroenterol Hepatol
Management of Crohn's disease in adults
Am J Gastroenterol
Therapeutic strategies for the management of ulcerative colitis
Inflamm Bowel Dis
Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis—methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa
Aliment Pharmacol Ther
Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis
Aliment Pharmacol Ther
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis
Aliment Pharmacol Ther
Infliximab for refractory ulcerative proctitis
Aliment Pharmacol Ther
Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis
Cochrane Database Syst Rev
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
Am J Gastroenterol
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Cochrane Database Syst Rev
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
Gut
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question
Aliment Pharmacol Ther
Infliximab for induction and maintenance therapy for ulcerative colitis
N Engl J Med
Cited by (190)
Oral chondroitin sulfate functionalized natural polyphenol for targeted therapy of ulcerative colitis
2024, Materials and DesignRecent advances in the treatment of IBD: Targets, mechanisms and related therapies
2023, Cytokine and Growth Factor ReviewsWielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease
2023, Journal of Controlled ReleaseIBD disease-modifying therapies: insights from emerging therapeutics
2023, Trends in Molecular MedicineOverview of microbial therapeutics in immunological disorders
2023, Microbiome Therapeutics: Personalized Therapy Beyond Conventional Approaches
Conflicts of interest This author discloses the following: Dr Travis has acted as an advisor to and is in receipt of unrestricted educational grants or speaker's honoraria from: Abbott, Asahi, Ferring, Genzyme, Merck, Novartis, Procter & Gamble, Schering–Plough, Tillotts, and UCB. The remaining author discloses no conflicts.